Back to Search Start Over

Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures.

Authors :
Huang CF
Chen JF
Reid IR
Chan WP
Ebeling PR
Langdahl B
Tu ST
Matsumoto T
Chan DC
Chung YS
Chen FP
Lewiecki EM
Tsai KS
Yang RS
Ang SB
Huang KE
Chang YF
Chen CH
Lee JK
Ma HI
Xia W
Mithal A
Kendler DL
Cooper C
Hwang JS
Wu CH
Source :
Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2023; Vol. 122 Suppl 1, pp. S14-S20. Date of Electronic Publication: 2023 Feb 10.
Publication Year :
2023

Abstract

Postmenopausal women are at significant risk for osteoporotic fractures due to their rapid bone loss. Half of all postmenopausal women will get an osteoporosis-related fracture over their lifetime, with 25% developing a spine deformity and 15% developing a hip fracture. By 2050, more than half of all osteoporotic fractures will occur in Asia, with postmenopausal women being the most susceptible. Early management can halt or even reverse the progression of osteoporosis. Consequently, on October 31, 2020, the Taiwanese Osteoporosis Association hosted the Asia-Pacific (AP) Postmenopausal Osteoporotic Fracture Prevention (POFP) consensus meeting, which was supported by the Asian Federation of Osteoporosis Societies (AFOS) and the Asia Pacific Osteoporosis Foundation (APOF). International and domestic experts developed ten applicable statements for the prevention of osteoporotic fractures in postmenopausal women with low bone mass or osteoporosis but no fragility fractures in the AP region. The experts advocated, for example, that postmenopausal women with a high fracture risk be reimbursed for pharmaceutical therapy to prevent osteoporotic fractures. More clinical experience and data are required to modify intervention tactics.<br />Competing Interests: Declaration of competing interest Chih-Hsing Wu received honoraria for lectures, attending meetings, and/or travel from Eli Lilly, Roche, Amgen, Merck, Servier laboratories, GE Lunar, Harvester, TCM Biotech, and Alvogen/Lotus. E Michael Lewiecki is an investigator, consultant, and speaker for Amgen, and an investigator for Radius.<br /> (Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
0929-6646
Volume :
122 Suppl 1
Database :
MEDLINE
Journal :
Journal of the Formosan Medical Association = Taiwan yi zhi
Publication Type :
Academic Journal
Accession number :
36775679
Full Text :
https://doi.org/10.1016/j.jfma.2023.01.013